	US 11,866,496 B2
	Humanized anti-CD79B antibodies and immunoconjugates and methods of use
Yvonne Chen, San Mateo, CA (US); Mark Dennis, San Carlos, CA (US); Kristi Elkins, San Francisco, CA (US); Jagath Reddy Junutula, Fremont, CA (US); Andrew Polson, San Francisco, CA (US); and Bing Zheng, Mountain View, CA (US)
Assigned to Genentech, Inc., South San Francisco, CA (US)
Filed by Genentech, Inc., South San Francisco, CA (US)
Filed on Apr. 19, 2021, as Appl. No. 17/234,695.
Application 17/234,695 is a division of application No. 15/803,495, filed on Nov. 3, 2017, granted, now 10,981,987.
Application 15/803,495 is a division of application No. 12/173,667, filed on Jul. 15, 2008, granted, now 9,845,355, issued on Dec. 19, 2017.
Claims priority of provisional application 60/950,088, filed on Jul. 16, 2007.
Prior Publication US 2022/0023437 A1, Jan. 27, 2022
Int. Cl. C07K 16/00 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61K 39/395 (2006.01); A61K 51/10 (2006.01); A61K 47/68 (2017.01); C07K 17/00 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2803 (2013.01) [A61K 39/39541 (2013.01); A61K 39/39558 (2013.01); A61K 47/6849 (2017.08); A61K 51/1027 (2013.01); C07K 16/2896 (2013.01); C07K 16/3061 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/92 (2013.01); Y02A 50/30 (2018.01)]

31 Claims

1. An immunoconjugate comprising an anti-CD79b antibody covalently attached to a cytotoxic agent, wherein the anti-CD79b antibody comprises:

i) an HVR-L1 comprising the sequence of SEQ ID NO: 23;

ii) an HVR-L2 comprising the sequence of SEQ ID NO: 24;

iii) an HVR-L3 comprising the sequence of SEQ ID NO: 25;

iv) an HVR-H1 comprising the sequence of SEQ ID NO: 31;

v) an HVR-H2 comprising the sequence of SEQ ID NO: 32; and

vi) an HVR-H3 comprising the sequence of SEQ ID NO: 33.